Efficacy of Iron Bisglycinate in Treatment of Iron Deficiency Anemia in Pregnant Women
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03378791 |
Recruitment Status :
Completed
First Posted : December 20, 2017
Last Update Posted : December 20, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Anemia in pregnancy is defined by the World Health Organization as hemoglobin levels of ≤ 11 g/dl. Globally, a prevalence rate of 38% was estimated by the World Health Organization for pregnant women.Treatment of iron deficiency anemia during pregnancy remains a main public health issue. Oral iron salts have been recommended for treatment of iron deficiency anemia e.g. ferrous fumarate. Increasing the dose of ferrous fumarate will subsequently increase the bioavailability of iron preparation, however it also increases the frequency of gastrointestinal tract side effects e.g. nausea, constipation, diarrhea, flatulence, and black stained stools. Besides, the increased bioavailable ferrous fumarate may decrease by many foods and / or chelating drugs in the gastrointestinal tract which interfere with its absorption leading to variability in the hemoglobin correction during the treatment.
Ferrous bisglycinate is an iron amino acid chelate. It is formed by reaction of ferrous iron with two molecules of the amino acid glycine by a covalent bound in a process called chelation. Ferrous bisglycinate is claimed to have better patient compliance because of fewer gastrointestinal tract side effects. It is also claimed that ferrous bisglycinate improves iron absorption, storage and increase hemoglobin level better than the conventionally used iron salts.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Iron Deficiency Anemia of Pregnancy | Drug: Iron bisglycinate Oral Tablet Drug: Ferrous Fumarate Oral Tablet | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 120 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Iron Bisglycinate Chelate or Ferrous Fumarate in Treatment of Iron Deficiency Anemia in Pregnant Women |
Actual Study Start Date : | December 31, 2015 |
Actual Primary Completion Date : | October 31, 2017 |
Actual Study Completion Date : | October 31, 2017 |
Arm | Intervention/treatment |
---|---|
Experimental: Group A
Iron bisglycinate (27mg of elemental iron)
|
Drug: Iron bisglycinate Oral Tablet |
Active Comparator: Group B
Ferrous fumarate (115mg of elemental iron)
|
Drug: Ferrous Fumarate Oral Tablet |
- Hemoglobin level [ Time Frame: At 4 weeks ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years to 40 Years (Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Pregnant women aged 20 to 40 years,
- 14-27 gestational weeks calculated from the first day of their last menstrual period and confirmed by ultrasound
- Singleton fetus
- hemoglobin level from 7-9.9 g/dL.
Exclusion Criteria:
- All women with high risk pregnancy e.g. hypertension, diabetes
- multiple pregnancy
- women with severe anemia (Hb >7 g/dl)
- anemia due to other causes than iron deficiency as chronic blood loss, hemolytic anemia or thalassemia.
- women with hepatic, renal or cardiovascular abnormality; women with peptic ulcer, esophagitis, gastritis or hiatus hernia
- family history of thalassemia, sickle cell anemia, or malabsorption syndrome
- hypersensitivity to iron preparations or current use of iron supplementation.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03378791
Egypt | |
Mansoura University Hospitals | |
Mansourah, Dakahlia Governorate, Egypt |
Study Chair: | Hatem Abu Hashim, MD. MRCOG. PhD | Faculty of Medicine, Mansoura University | |
Principal Investigator: | Ahmed Ismail, MBBCh | Mansoura University Hospital |
Responsible Party: | Hatem AbuHashim, Professor, Mansoura University |
ClinicalTrials.gov Identifier: | NCT03378791 |
Other Study ID Numbers: |
MS/15.10.05 |
First Posted: | December 20, 2017 Key Record Dates |
Last Update Posted: | December 20, 2017 |
Last Verified: | December 2017 |
Anemia Anemia, Iron-Deficiency Iron Deficiencies Deficiency Diseases Hematologic Diseases Iron Metabolism Disorders Metabolic Diseases |
Anemia, Hypochromic Malnutrition Nutrition Disorders Ferrous fumarate Trace Elements Micronutrients Physiological Effects of Drugs |